• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration

    8/6/25 7:56:00 PM ET
    $ENTA
    $RNTX
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ENTA alert in real time by email

    Strategic partnership leverages AI and robotics for novel therapeutics across oncology, immunology, inflammation, neurology, and metabolic diseases.

    CAMBRIDGE, Mass., Aug. 6, 2025 /PRNewswire/ -- XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics for drug and materials discovery, announced a transformative strategic collaboration with DoveTree Medicines, a biotechnology pioneer founded by renowned drug developer Dr. Gregory Verdine. The collaboration, worth up to $5.99 billion, represents one of the largest commitments to date for AI- and robotics-driven pharmaceutical R&D.

    (PRNewsfoto/XtalPi Inc.)

    Under the agreement, DoveTree gains exclusive global rights to develop and commercialize a portfolio of innovative therapeutics generated through the partnership. XtalPi has received an upfront payment of $51 million and is eligible for $49 million in additional near-term payments, plus development and commercial milestones, as well as tiered royalties totaling up to $5.89 billion.

    This collaboration merges XtalPi's integrated drug discovery capabilities with DoveTree's deep biological expertise in selecting and validating novel targets of high therapeutic potential. Together, the companies will focus on developing first-in-class candidates across oncology, immunology and inflammatory diseases, neurological disorders, and metabolic dysregulation with significant unmet needs. The partnership will advance DoveTree's selected pipeline of projects targeting historically challenging mechanisms, with plans to expand joint R&D capabilities in emerging modalities like molecular glue.

    DoveTree Medicines was founded by Dr. Gregory Verdine, an internationally esteemed scientist, entrepreneur, and seasoned investor in the biopharmaceutical field, with outstanding achievements in both academia and industry. He has co-founded over a dozen biopharmaceutical companies, including more than five publicly listed firms such as Enanta Pharmaceuticals (NASDAQ:ENTA), Rein Therapeutics (NASDAQ:RNTX), and WaVe Life Sciences (NASDAQ:WVE). Credited with originating the "drugging the undruggable" concept, Dr. Verdine has pioneered unique molecular glue and peptide technology platforms, successfully applying them to the drug development against "undruggable" proteins such as RAS, Myc, and β-catenin. He has co-developed three FDA-approved drugs, with over a dozen additional candidates currently in clinical development.

    XtalPi has developed an intelligent de novo drug discovery platform that spans small molecules, biologics, antibody-drug conjugates (ADCs), and molecular glues. This multimodal capability enables the efficient exploration of parallel drug development approaches against single targets and unlocks broader chemical space. By integrating quantum physics predictions, AI-driven molecular design, and a large-scale robotic lab-in-the-loop, XtalPi significantly accelerates the drug discovery workflow—from target analysis and molecular generation to affinity prediction, ADMET assessment, and synthesis design—with enhanced accuracy and efficiency. Through extensive partnerships with innovative pharmaceutical companies, XtalPi's platform has been rigorously validated in real-world projects, accumulating vast datasets of standardized experimental data and high-precision computational data to continuously optimize models within a closed feedback loop.

    Dr. Gregory Verdine, Founder and Chief Executive Officer of DoveTree, stated: "XtalPi's unique platform has the potential to transform the profound uncertainties of drug discovery into quantifiable engineering solutions. Their demonstrated ability to innovate at scale makes them a valuable partner in pursuing drug targets that are beyond conventional methods. By merging DoveTree's biological insights and extensive R&D expertise with XtalPi's powerful platform, we aim to deliver transformative therapies for patients globally."

    Dr. Shuhao Wen, Chairman of XtalPi, commented: "Dr. Verdine and DoveTree bring exceptional biological acumen, business vision, and a proven track record of translational success, perfectly complementing our platform's strengths in high-throughput molecule generation, design, and validation. This partnership positions us to accelerate breakthroughs against complex diseases while expanding the frontiers of AI-driven drug discovery. XtalPi remains committed to advancing our core technologies and working closely with leading innovators to help build diverse pipelines of impactful medicines."

    About DoveTree Medicines

    DoveTree Medicines is a biotech company dedicated to discovering first-in-class medicines for diseases with profound unmet medical needs. Founded and led by distinguished scientist-entrepreneur Dr. Gregory Verdine, DoveTree integrates deep biological insight and advanced AI to unlock novel therapeutic pathways and accelerate the development of transformative medicines, translating pioneering science into meaningful patient benefit.

    About XtalPi

    XtalPi Holdings Limited (XtalPi, 2228.HK) was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/xtalpi-and-dovetree-announce-landmark-6-billion-ai-drug-discovery-collaboration-302523824.html

    SOURCE XtalPi Inc.

    Get the next $ENTA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ENTA
    $RNTX
    $WVE

    CompanyDatePrice TargetRatingAnalyst
    Rein Therapeutics Inc.
    $RNTX
    9/22/2025$10.00Buy
    H.C. Wainwright
    Wave Life Sciences Ltd.
    $WVE
    8/4/2025$19.00Buy
    Canaccord Genuity
    Wave Life Sciences Ltd.
    $WVE
    7/28/2025$24.00Outperform
    Oppenheimer
    Enanta Pharmaceuticals Inc.
    $ENTA
    7/28/2025$20.00Buy
    H.C. Wainwright
    Wave Life Sciences Ltd.
    $WVE
    7/16/2025$16.00Buy
    Citigroup
    Wave Life Sciences Ltd.
    $WVE
    6/11/2025$14.00Outperform
    Raymond James
    Wave Life Sciences Ltd.
    $WVE
    4/29/2025$10.00Overweight
    Cantor Fitzgerald
    Wave Life Sciences Ltd.
    $WVE
    4/8/2025$18.00Outperform
    Wedbush
    More analyst ratings

    $ENTA
    $RNTX
    $WVE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Luly Jay R. bought $256,050 worth of shares (45,000 units at $5.69), increasing direct ownership by 6% to 846,638 units (SEC Form 4)

    4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)

    2/12/25 8:09:35 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Gsk Plc bought $22,335,440 worth of Ordinary Shares (2,791,930 units at $8.00) (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    10/1/24 5:54:39 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gsk Plc bought $16,500,000 worth of Ordinary Shares (3,300,000 units at $5.00) (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    1/30/24 4:39:08 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTA
    $RNTX
    $WVE
    SEC Filings

    View All

    SEC Form 424B5 filed by Enanta Pharmaceuticals Inc.

    424B5 - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

    9/30/25 4:43:53 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enanta Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

    9/29/25 8:20:18 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enanta Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

    9/29/25 6:51:36 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTA
    $RNTX
    $WVE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Capps Kathleen S. claimed ownership of 5,829 shares (SEC Form 3)

    3 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)

    9/8/25 6:01:31 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Trout Harry R. Iii claimed ownership of 10,912 shares (SEC Form 3)

    3 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)

    9/8/25 6:00:59 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Bolno Paul sold $2,194,810 worth of Ordinary Shares (217,351 units at $10.10), decreasing direct ownership by 64% to 121,000 units (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    8/26/25 9:40:04 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTA
    $RNTX
    $WVE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the pricing of an upsized underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $10.00 per share. All of the shares are being offered by Enanta. The offering is expected to close on October 2, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds to Enanta from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $65.0 million. In addition, Enanta has granted the underwri

    9/30/25 9:00:00 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced it has commenced an underwritten public offering for $50.0 million of shares of its common stock. All of the shares are being offered by Enanta. In addition, Enanta intends to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be compl

    9/30/25 4:11:00 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults

    6.7-Day Improvement in Time to Complete Resolution of All RSV Symptoms for Patients with Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF), or Age ≥75 Statistically Significant Improvement in Patient Global Impression of Severity Score Lower Hospitalization Rate for Patients Treated with Zelicapavir (1.7%) vs. Placebo (5%) 4- to 5-Day Faster Median Time to Undetectable Viral Load with Zelicapavir vs. Placebo Management to Host Conference Call and Webcast Today at 8:30 a.m. ET Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases,

    9/29/25 6:30:00 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTA
    $RNTX
    $WVE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Rein Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Rein Therapeutics with a rating of Buy and set a new price target of $10.00

    9/22/25 8:32:15 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Wave Life Sciences with a new price target

    Canaccord Genuity initiated coverage of Wave Life Sciences with a rating of Buy and set a new price target of $19.00

    8/4/25 8:22:27 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Wave Life Sciences with a new price target

    Oppenheimer initiated coverage of Wave Life Sciences with a rating of Outperform and set a new price target of $24.00

    7/28/25 9:02:28 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTA
    $RNTX
    $WVE
    Leadership Updates

    Live Leadership Updates

    View All

    Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer

    CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Christopher Wright, MD, PhD, as Chief Medical Officer. Dr. Wright will join Wave's executive team and lead global development, including medical, clinical and regulatory functions, to bring the company's RNA medicines to countless individuals who urgently need them. "Dr. Wright joins us with extensive global development leadership experience spanning both early and late-stage clinical development, including an impressive track-record of success

    5/28/25 8:00:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer

    CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Erik Ingelsson, MD, PhD, as Chief Scientific Officer. Dr. Ingelsson will drive Wave's emerging therapeutic portfolio strategy, including growing its genetics and genomics capabilities for identifying new, high impact targets, and leveraging the company's best-in-class multimodal discovery and development platform to advance transformative RNA medicines. Most recently, Dr. Ingelsson served as Senior Vice President, Head of Target Discovery, at GSK

    5/9/24 7:00:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the appointment of Matthew P. Kowalsky, J.D., as Chief Legal Officer. In this role, he will lead all legal and compliance activities for Enanta, as well as provide strategic guidance and corporate governance oversight. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240430622885/en/Matthew P. Kowalsky, Chief Legal Officer, Enanta Pharmaceuticals, Inc. (Photo: Business Wire) "I'm pleased to welcome Matt to Enanta. The breadth of his legal expertise ac

    4/30/24 7:00:00 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTA
    $RNTX
    $WVE
    Financials

    Live finance-specific insights

    View All

    Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults

    6.7-Day Improvement in Time to Complete Resolution of All RSV Symptoms for Patients with Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF), or Age ≥75 Statistically Significant Improvement in Patient Global Impression of Severity Score Lower Hospitalization Rate for Patients Treated with Zelicapavir (1.7%) vs. Placebo (5%) 4- to 5-Day Faster Median Time to Undetectable Viral Load with Zelicapavir vs. Placebo Management to Host Conference Call and Webcast Today at 8:30 a.m. ET Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases,

    9/29/25 6:30:00 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults

    Conference Call and Webcast to Discuss Data on Monday, September 29 at 8:30 a.m. ET Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced the company will hold a conference call and webcast on Monday, September 29 at 8:30 a.m. ET to share topline results from RSVHR, a Phase 2b study evaluating zelicapavir for the treatment of respiratory syncytial virus (RSV) in high-risk adults. Conference Call and Webcast Information The live webcast can be accessed at "Events & Presentations" in the investors section of Enanta's website. To participate by phone

    9/26/25 4:01:00 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

    Achieved durable production of serum AAT protein at levels associated with a lower risk of AATD liver and lung diseases following repeat 200 mg doses of WVE-006 (11.9 µM total AAT, 7.2 µM M-AAT)  First-ever demonstration of therapeutically restored physiological serum AAT production in a Pi*ZZ individual during a non-drug related acute phase response (20.6 µM total AAT, 10.3 µM M-AAT) Single dose of 400 mg achieved 12.8 µM total AAT and 5.3 µM M-AAT; ongoing 400 mg multidose cohort has potential to deliver further increases in serum AAT Data from 200 mg and 400 mg cohorts support monthly or less frequent subcutaneous dosing; 400 mg monthly multidose cohort data expected in 1Q 2026 WVE-0

    9/3/25 7:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTA
    $RNTX
    $WVE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Enanta Pharmaceuticals Inc.

    SC 13G/A - ENANTA PHARMACEUTICALS INC (0001177648) (Subject)

    11/14/24 4:03:02 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Wave Life Sciences Ltd.

    SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

    11/12/24 4:30:35 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Wave Life Sciences Ltd.

    SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

    11/12/24 9:34:18 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care